Discovery Laboratories, Inc. (NASDAQ:DSCO)

Looks good

s50.1>67,s20.1<50,s5.1<33&C>C1

Discovery's stock is the epitome of irony, having failed to display any sustained strength despite the long-awaited FDA approval of Surfaxin. Many are skeptical if this ne'er-do-well will actually find a way to compete with established animal surfactants once Surfaxin becomes available at the end of 2012, or if they'll suddenly announce another 50M dilutive financing followed by a six month delay. I'm a little too cynical to buy in again, after barely escaping with my skin intact from my last ill-fated venture, but I'll let this green-thumb mark the stock for re-evaluation in a few months.

Felt it was a good time to close and re-open. Started adding back shares at 2.85 now that the dilution has arrived. This doesn't have the same speculative potential at these levels but I also don't feel that the risk is what it once was...they do have a product to sell now and other products in the pipeline to push along as well...

Climb on my little DSCO...Climb on!

Biotech watchlist

I think JNJ will buy this stock

FDA gamble.

likely fda approval, plenty of time for the company to get the manufacturing issue out of the way.

Completely speculative.

History always seems to repeats itself...

Riding out the storm till patent is approved or not.

Should go higher now that Porte has capitulated! Seems that small biotech has taken the interest of the big boys with recent increases in price and volume.

Down we go!

FDA approval of its major drug Surfaxin will push share price to at least 10.

DSCO has comeout with a positive outlook during the last couple of weeks. The trend looks to be positive since they have currently completed batch 1 of trials and are waiting to complete the remaining 3 batches which will be sufficient enough to fulfill the needs of the FDA. The outlook looks promising enough with the financials too since they have a positive cash flow and are ready to submit to the FDA in early third quarter. With all this components which adds up to a successful progression towards the completion of FDA needs and requirements. My Target will be $10 to $12 before the early fouth quarter and then rise upto to $25 to $35 after the approval. ( which will still be about a $1.7 to $2 before the reverse split. )

see this post.
http://caps.fool.com/Blogs/dsco/539223.

Momentum21 haiku

Disco is not dead

The FDA has it wrong

Rise up from the ash

close to " yl" price this is a bargain price and undervalued.

This is a swing for the fences. Hope it goes up as they get closer to FDA decision. Do you hang on for the ride up or down after the decision comes? Only buy with money you can spare because this one could go either way.